Table 4.
Effects of Sildenafil on Exercise Reserve Responses
| Placebo (N=25) | Sildenafil (N=23) | P value* | P-value** | |
|---|---|---|---|---|
| 12 Weeks | ||||
|
| ||||
| Baseline SBP, low (mmHg, n=25/22) | 131 ± 18 | 138 ± 18 | ||
| Week 12 SBP, low (mmHg, n=25/22) | 133 ± 16 | 129 ± 23 | ||
| ΔSBP, low | 2 ± 21 | −9 ± 16 | 0.15 | 0.3 |
|
| ||||
| Baseline SBP, peak (mmHg, n=25/23) | 163 ± 23 | 169 ± 24 | ||
| Week 12 SBP, peak (mmHg, n=25/23) | 166 ± 24 | 165 ± 24 | ||
| ΔSBP, peak | 3 ± 19 | −3 ± 16 | 0.3 | 0.4 |
|
| ||||
| Baseline DBP, low (mmHg, n=25/22) | 72 ± 9 | 75 ± 13 | ||
| Week 12 DBP, low (mmHg, n=25/22) | 72 ± 8 | 72 ± 10 | ||
| ΔDBP, low | −0.2 ± 9 | −3 ± 13 | 0.6 | 0.7 |
|
| ||||
| Baseline DBP, peak (mmHg, n=25/23) | 71 ± 13 | 77 ± 15 | ||
| Week 12 DBP, peak (mmHg, n=25/23) | 73 ± 14 | 74 ± 12 | ||
| ΔDBP, peak | 2 ± 13 | −3 ± 12 | 0.4 | 0.4 |
|
| ||||
| Baseline HR, low (mmHg, n=25/23) | 80 ± 12 | 83 ± 16 | ||
| Week 12 HR, low (mmHg, n=25/23) | 79 ± 11 | 79 ± 17 | ||
| ΔHR, low | −1 ± 9 | −4 ± 9 | 0.3 | 0.4 |
|
| ||||
| Baseline HR, peak (mmHg, n=25/23) | 110 ± 19 | 119 ± 25 | ||
| Week 12 HR, peak (mmHg, n=25/23) | 109 ± 18 | 108 ± 19 | ||
| ΔHR, peak | −1 ± 13 | −11 ± 19 | 0.11 | 0.08 |
|
| ||||
| Baseline EF, low (mmHg, n=22/20) | 62 ± 6 | 61 ± 6 | ||
| Week 12 EF, low (mmHg, n=22/20) | 61 ± 6 | 63 ± 5 | ||
| ΔEF, low | −1 ± 6 | 2 ± 4 | 0.054 | 0.09 |
|
| ||||
| Baseline EF, peak (mmHg, n=19/18) | 68 ± 6 | 66 ± 6 | ||
| Week 12 EF, peak (mmHg, n=19/18) | 64 ± 7 | 68 ± 6 | ||
| ΔEF, peak | −3 ± 6 | 2 ± 4 | 0.008 | 0.01 |
| 24 Weeks | ||||
|
| ||||
| Baseline SBP, low (mmHg, n=24/23) | 130 ± 18 | 140 ± 19 | ||
| Week 24 SBP, low (mmHg, n=24/23) | 133 ± 16 | 130 ± 28 | ||
| ΔSBP, low | 3 ± 16 | −9 ± 19 | 0.047 | 0.07 |
|
| ||||
| Baseline SBP, peak (mmHg, n=24/23) | 163 ± 24 | 169 ± 24 | ||
| Week 24 SBP, peak (mmHg, n=24/23) | 162 ± 25 | 163 ± 30 | ||
| ΔSBP, peak | −0.2 ± 19 | −5 ± 22 | 0.5 | 0.5 |
|
| ||||
| Baseline DBP, low (mmHg, n=24/23) | 72 ± 9 | 75 ± 13 | ||
| Week 24 DBP, low (mmHg, n=24/23) | 71 ± 11 | 70 ± 9 | ||
| ΔDBP, low | −1 ± 10 | −5 ± 13 | 0.5 | 0.4 |
|
| ||||
| Baseline DBP, peak (mmHg, n=24/23) | 70 ± 12 | 77 ± 15 | ||
| Week 24 DBP, peak (mmHg, n=24/23) | 71 ± 15 | 72 ± 13 | ||
| ΔDBP, peak | 1 ± 12 | −6 ± 12 | 0.2 | 0.2 |
|
| ||||
| Baseline HR, low (mmHg, n=24/23) | 80 ± 12 | 83 ± 16 | ||
| Week 24 HR, low (mmHg, n=24/23) | 79 ± 10 | 77 ± 14 | ||
| ΔHR, low | −1 ± 9 | −6 ± 10 | 0.07 | 0.09 |
|
| ||||
| Baseline HR, peak (mmHg, n=24/23) | 109 ± 19 | 119 ± 25 | ||
| Week 24 HR, peak (mmHg, n=24/23) | 110 ± 19 | 107 ± 24 | ||
| ΔHR, peak | 1 ± 13 | −12 ± 19 | 0.02 | 0.01 |
|
| ||||
| Baseline EF, low (mmHg, n=25/22) | 62 ± 5 | 61 ± 6 | ||
| Week 24 EF, low (mmHg, n=25/22) | 62 ± 6 | 62 ± 6 | ||
| ΔEF, low | −0.2 ± 6 | 0.3 ± 5 | 0.99 | 0.93 |
|
| ||||
| Baseline EF, peak (mmHg, n=20/18) | 68 ± 6 | 66 ± 6 | ||
| Week 24 EF, peak (mmHg, n=20/18) | 66 ± 6 | 66 ± 6 | ||
| ΔEF, peak | −1 ± 6 | 1 ± 6 | 0.5 | 0.6 |
*
P-values adjusted for baseline
**
P-values adjusted for age and baseline
Column 1 parentheses indicate number of placebo/sildenafil subjects with available data for each parameter.